clinical trial · NCT02390297
Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients
Calimmune, Inc.·—·active not recruiting·n = 11
HIV-1 InfectionReceipt of Cal-1 Modified Hematopoietic Cellular ProductsBlood tests
brief summary
Long term safety follow-up of Cal-1 recipients
started
Apr 1, 2015
primary completion
Oct 1, 2031
completion
Oct 1, 2031
last updated
Oct 10, 2025
detailed description
Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced with LVsh5/C46 (Cal-1), a Dual Anti-HIV Gene Transfer Construct
official title
Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol